Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free EVFM Stock Alerts

Evofem Biosciences (EVFM) Competitors

Evofem Biosciences logo
$0.0060 0.00 (-10.45%)
As of 03:58 PM Eastern
Compare

EVFM vs. MYNZ, PULM, CAPS, REVB, and SXTP

Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Mainz Biomed (MYNZ), Pulmatrix (PULM), Capstone Therapeutics (CAPS), Revelation Biosciences (REVB), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry.

How does Evofem Biosciences compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

0.2% of Evofem Biosciences shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Evofem Biosciences had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Mainz Biomed. Evofem Biosciences' average media sentiment score of 1.34 beat Mainz Biomed's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Mainz Biomed Neutral
Evofem Biosciences Positive

Evofem Biosciences has higher revenue and earnings than Mainz Biomed. Evofem Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$659.94K5.49-$21.65M-$65.60N/A
Evofem Biosciences$11.39M0.07$52.98M-$0.03N/A

Mainz Biomed has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Mainz Biomed's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
Evofem Biosciences -46.42%-91.97%-61.93%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the S&P 500.

Summary

Mainz Biomed beats Evofem Biosciences on 8 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evofem Biosciences had 1 more articles in the media than Pulmatrix. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Pulmatrix. Evofem Biosciences' average media sentiment score of 1.34 beat Pulmatrix's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Pulmatrix Neutral
Evofem Biosciences Positive

Evofem Biosciences has higher revenue and earnings than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PulmatrixN/AN/A-$5.16M-$1.41N/A
Evofem Biosciences$11.39M0.07$52.98M-$0.03N/A

Pulmatrix has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
PulmatrixN/A -96.97% -88.53%
Evofem Biosciences -46.42%-91.97%-61.93%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Pulmatrix has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the S&P 500.

Summary

Evofem Biosciences beats Pulmatrix on 8 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to Capstone Therapeutics?

Evofem Biosciences (NASDAQ:EVFM) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.52, meaning that its stock price is 252% less volatile than the S&P 500.

Evofem Biosciences has higher earnings, but lower revenue than Capstone Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.07$52.98M-$0.03N/A
Capstone Therapeutics$46.88M0.12-$21.23M-$3.63N/A

In the previous week, Evofem Biosciences had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Capstone Therapeutics. Evofem Biosciences' average media sentiment score of 1.34 beat Capstone Therapeutics' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evofem Biosciences Positive
Capstone Therapeutics Neutral

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 59.1% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Capstone Therapeutics has a net margin of -45.01% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Capstone Therapeutics -45.01%-93.49%-39.69%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Evofem Biosciences and Capstone Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to Revelation Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Evofem Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500.

Evofem Biosciences has higher revenue and earnings than Revelation Biosciences. Evofem Biosciences is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.07$52.98M-$0.03N/A
Revelation BiosciencesN/AN/A-$8.91M-$62.09N/A

In the previous week, Evofem Biosciences had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Revelation Biosciences. Evofem Biosciences' average media sentiment score of 1.34 beat Revelation Biosciences' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evofem Biosciences Positive
Revelation Biosciences Neutral

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 8.0% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Revelation Biosciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Revelation Biosciences N/A -134.18%-105.47%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Evofem Biosciences beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals presently has a consensus price target of $14.10, suggesting a potential upside of 754.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Evofem Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Evofem Biosciences has higher revenue and earnings than 60 Degrees Pharmaceuticals. Evofem Biosciences is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M3.09-$7.36M-$13.88N/A
Evofem Biosciences$11.39M0.07$52.98M-$0.03N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 1.34 beat 60 Degrees Pharmaceuticals' score of 0.49 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Evofem Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Evofem Biosciences has a net margin of -46.42% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-550.67% N/A -132.47%
Evofem Biosciences -46.42%-91.97%-61.93%

60 Degrees Pharmaceuticals has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500.

Summary

60 Degrees Pharmaceuticals beats Evofem Biosciences on 9 of the 16 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVFM vs. The Competition

Export
MetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$795K$889.45M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio-0.011.7129.0428.48
Price / Sales0.07120.50476.4860.89
Price / CashN/A20.0727.6236.52
Price / Book0.007.609.676.67
Net Income$52.98M-$4.80M$3.55B$332.64M
7 Day PerformanceN/A-0.05%1.70%2.01%
1 Month PerformanceN/A5.50%5.62%9.19%
1 Year PerformanceN/A30.96%34.42%39.59%

Evofem Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVFM
Evofem Biosciences
N/A$0.01
-10.4%		N/AN/A$795K$11.39MN/A120
MYNZ
Mainz Biomed
N/A$0.50
-7.0%		N/AN/A$4.55M$659.94KN/A30
PULM
Pulmatrix
0.386 of 5 stars		$1.24
-3.1%		N/AN/A$4.53MN/AN/A20
CAPS
Capstone Therapeutics
0.7867 of 5 stars		$0.38
-7.2%		N/AN/A$4.35M$46.88MN/A38
REVB
Revelation Biosciences
0.9495 of 5 stars		$1.15
-0.9%		N/AN/A$4.28MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel